Malondialdehyde-acetaldehyde (MAA) adducted surfactant protein induced lung inflammation is mediated through scavenger receptor a (SR-A1) by unknown
RESEARCH Open Access
Malondialdehyde-acetaldehyde (MAA)
adducted surfactant protein induced lung
inflammation is mediated through
scavenger receptor a (SR-A1)
Muna Sapkota1, Jane M. DeVasure2, Kusum K. Kharbanda3,4 and Todd A. Wyatt1,2,4*
Abstract
Background: Co-exposure to cigarette smoke and alcohol leads to the generation of high concentrations of
acetaldehyde and malondialdehyde in the lung. These aldehydes being highly electrophilic in nature react with
biologically relevant proteins such as surfactant protein D (SPD) through a Schiff base reaction to generate SPD
adducted malondialdehyde-acetaldehyde adduct (SPD-MAA) in mouse lung. SPD-MAA results in an increase in lung
pro-inflammatory chemokine, keratinocyte chemoattractant (KC), and the recruitment of lung lavage neutrophils.
Previous in vitro studies in bronchial epithelial cells and macrophages show that scavenger receptor A (SR-A1/CD204) is
a major receptor for SPD-MAA. No studies have yet examined the in vivo role of SR-A1 in MAA-mediated lung
inflammation. Therefore, we hypothesize that in the absence of SR-A1, MAA-induced inflammation in the lung is
reduced or diminished.
Methods: To test this hypothesis, C57BL/6 WT and SR-A1 KO mice were nasally instilled with 50 μg/mL of SPD-MAA
for 3 weeks (wks). After 3 weeks, bronchoalveolar lavage (BAL) fluid was collected and assayed for a total cell count, a
differential cell count and CXCL1 (KC) chemokine. Lung tissue sections were stained with hematoxylin and eosin (H&E)
and antibodies to MAA adduct.
Results: Results showed that BAL cellularity and influx of neutrophils were decreased in SR-A1 KO mice as compared
to WT following repetitive SPD-MAA exposure. MAA adduct staining in the lung epithelium was decreased in SR-A1 KO
mice. In comparison to WT, no increase in CXCL1 was observed in BAL fluid from SR-A1 KO mice over time.
Conclusions: Overall, the data demonstrate that SR-A1/CD204 plays an important role in SPD-MAA induced
inflammation in lung.
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Background
People who abuse alcohol are likely to smoke cigarettes,
and similarly, smokers are more likely to drink alcohol
than non-smokers [1]. Among individuals with alcohol
use disorders (AUDs), smoking rates are estimated to be
90% and more than 70% of these individuals smoke at
least one pack of cigarettes per day [2, 3]. Well estab-
lished as the major cause of all lung cancers, cigarette
smoking is also a risk factor for respiratory tract infec-
tions like pneumonia and tuberculosis. Smoking is also
the primary risk factor for chronic obstructive pulmon-
ary disease (COPD) [4], projected to be the third leading
global cause of death by 2030 [5]. Because the chronic
consumption of alcohol has a wide range of effects on
lung function, it could increase the risks of pneumonia,
acute respiratory distress syndrome (ARDS) [6] and
COPD [7].
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Although most ingested alcohol is metabolized in the
liver, significant concentrations of ethanol reach the air-
way passages via the bronchial circulation [8]. In the
lung of chronic alcohol drinkers, airways can be con-
tinuously exposed to high concentrations of alcohol due
to the “recycling” of alcohol vapor [9]. Generally, alcohol
is metabolized by the alcohol dehydrogenase (ADH)
pathway to generate acetaldehyde [8]. In chronic alcohol
consumption, however, the CYP2E1 pathway is induced,
leading to oxidative stress, lipid peroxidation and gener-
ation of malondialdehyde [10, 11]. In alcohol abusers
who smoke cigarettes, even higher concentrations of re-
active aldehydes are formed in the lung. Metabolism of
alcohol through ADH and CYP2E1 leads to generation
of acetaldehyde (AA) and malondialdehyde (MDA) [12].
In addition, pyrolysis of tobacco generates high concen-
trations of AA [13]. Cigarette smoke also induces oxida-
tive stress, leading to lipid peroxidation resulting in high
concentrations of MDA [14]. These aldehydes in lung,
being highly reactive and electrophilic, bind to nucleo-
philic sites on proteins through a Schiff base reaction
[15], leading to the formation of hybrid protein adducts.
Unlike other individual aldehyde protein adducts, this
hybrid malondialdehyde-acetaldehyde (MAA) adduct is
very stable [16]. The lungs of alcohol abusers who also
smoke cigarettes are the ideal environment for the for-
mation of MAA adduct [17]. Lung surfactant protein D
(SPD), produced by type II alveolar epithelial cells, is
one target protein adducted by reactive aldehydes to
form SPD-MAA [17]. MAA adducts in lung have been
shown to delay wound healing and increase protein kin-
ase C-dependent IL-8 release as well as decrease cilia
beating frequency [18, 19]. Additionally, MAA adducted
protein instilled into lungs of mice produce inflamma-
tory injury [20].
Scavenger receptor A (SR-A1/CD204) expression is
mainly confined to macrophages but is also present on
dendritic cells, endothelial cells, Kupffer cells, airway
epithelial cells and vascular smooth muscle cells [21,
22]. SR-A1 plays an important, well-established role in
atherosclerosis [23–25]. SR-A1 can bind to a broad
range of ligands such as oxidized LDL, acetylated LDL,
fucoidan, dextran sulfate and modified self proteins [26]
as well as a number of conserved microbial structures,
such as bacterial lipopolysaccharide and lipoteichoic acid
[27]. Based upon in vitro evidence, SR-A1 may play an
important role in innate immunity, and an affinity for
modified lipids and pathogens might suggest its role in
inflammation [28]. SR-A1 has been shown to be import-
ant in the uptake of the MAA adduct in bronchial epi-
thelial cells [29] and liver sinusoidal endothelial cells
[30]. Absence of this receptor has been shown to reduce
IL-8 release from mouse tracheal epithelial cells [29] as
well as decrease antibody response to malondialdehyde
acetaldehyde albumin (MAA-Alb) [30]. SR-A1 has also
been shown to be one of the primary receptors for MAA
adduct on macrophages [31].
Our previous study in mice shows that MAA has a
pro-inflammatory effect in lung after 3 weeks of instilla-
tion as an increase in the pro-inflammatory chemokine,
keratinocyte chemoattractant (KC; CXCL1), and lung
lavage neutrophils was observed [20]. In both bronchial
epithelial cells and macrophages, SR-A1 primarily binds
MAA adducts [29, 31] and plays an important role initi-
ating MAA-mediated effects. However, the role of SR-
A1 in MAA adduct-mediated lung inflammation and in-
jury has not yet been studied, therefore we hypothesized
that SR-A1 has an important role in MAA-mediated
lung inflammation, and that in the absence of this recep-
tor, the effects of MAA in mouse lung is decreased. We
show, for the first time, the role of SR-A1 in MAA-
mediated lung inflammatory effects in a mouse model.
Methods
Mice
WT C57BL/6 mice were purchased from the Charles
River (Wilmington, MA) at 6–8 weeks of age and SR-A1
(CD204) knockout mice on C57BL/6 background were
bred from homozygous SR-A1-deficient mice (−/−)
(B6.Cg-Msr1tm1Csk/J; Jackson Laboratory, Bar Harbor,
ME). All mice were housed in group cages and received
standard rodent chow and water ad libitum for 1 week
before the start of the experiment. Mice were monitored
daily and weighed weekly. All experimental protocols
were reviewed and approved by the Institutional Animal
Care and Use Committee of the University of Nebraska
Medical Center (protocol number 04-059-08).
Preparation of MAA adducted protein
Human surfactant protein D (SPD) adducted to MAA
(SPD-MAA) was prepared as previously reported [20].
Briefly, approximately 1–1.5 mg/mL of SPD was incu-
bated with 1.0 mM acetaldehyde and 1.0 mM MDA in
pyrogen-free PBS. The pH was brought to 7.4, and
maintained at 37 °C for 72 h. At the end of incubation,
the reaction mixture was exhaustively dialyzed against
pyrogen-free phosphate buffer solution for 24 h at 4 °C.
The endotoxin level in the MAA-SPD was measured by
limulus assay and was below the limit of detection.
Intranasal instillation
The intranasal instillation was performed as previously
described [20]. Briefly, mice were first assigned to three
treatment groups: saline, SPD and SPD-MAA. Non-
adducted protein control (SPD) was used to rule out any
potential immunological side effects. All three treat-
ments (saline, SPD-MAA and SPD) were sterile and free
of endotoxin. For intranasal instillation each mouse was
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anesthetized using isoflurane inhalation and then posi-
tioned with its head held back to make the nasal path-
way vertical. 50 μL of the treatment solution (sterile
saline or 50 μg/mL of SPD-MAA or SPD) was gently
placed on the nasal openings with a pipette tip. After the
instillation, each mouse was held in the same position to
ensure complete inhalation and then monitored until it
was awake and moving around normally. This procedure
was done one time and also repeated daily for 1–3 weeks.
None of the mice showed any sign of distress.
Bronchoalveolar lavage (BAL)
After the instillation period, mice were euthanized by
isoflurane overdose. The trachea was then exposed and a
cannula inserted just below the larynx. The proximal
end of the trachea was tied around the cannula and
1.0 mL of sterile PBS (Gibco, Grand Island, NY, USA)
was instilled into the lungs and recovered by aspiration
three separate times. The BAL fluid was centrifuged at
250 g to collect cells. The supernatant from the first pull
was stored at −80 °C for later analysis of cytokines/che-
mokines. Cells from the 3 ml were resuspended in PBS,
counted using a hemocytometer and then cytospun
(Cytopro Cytocentrifuge, Wescor Inc. Logan, UT, USA)
onto slides. The slides were stained with Hema three
stain set (Fisher, Kalamazoo, MI). Later, cell differential
counts were carried out on the slides with a minimum
of 200 cells per slide counted for differential analysis
per mouse.
Lung histology
After whole lung lavage, the lung from each treatment
group was tied with a suture thread via the trachea to
the cannula. Once tied, the lung was slowly removed
from the thoracic cavity. Then the lungs were slowly in-
flated with 1 mL of 10% formalin (Sigma, St. Louis,
MO). The lungs were hung under a pressure of
15 cmH2O for 24 h while submerged in 10% formalin to
obtain uniform lung inflation during fixation. Subse-
quently, the lung tissues were arranged in cassettes and
send to a tissue processing facility where the lung tissue
were dehydrated and embedded in paraffin. 5 μm sec-
tions were made from lung tissue. The sections were
stained for hematoxylin and eosin (H&E) or utilized later
for immunohistochemistry. Each slide was reviewed at
scanning magnifications (×2, ×4, and ×10 objectives;
Nikon Eclipse model E600 microscope). The slides were
reviewed to assess the influx of inflammatory cells
(mostly neutrophils).
Immunohistochemistry
Immunohistochemical staining of the lung tissue section
was performed as previously reported [31] with slight
modification. Formalin-fixed, paraffin-embedded
sections of 5 μm thick tissue were deparaffinized
through Safeclear II™ tissue clearing agent (Fisher) and
later rehydrated using a graded series of alcohol washes
(100, 95, 80, 50% ethanol). The slides were then rinsed
three times in PBS. A heat-induced epitope retrieval
method was performed for antigen unmasking. Briefly,
slides were immersed in preheated antigen retrieval so-
lution (DIVA Decloaker solution; Biocare Medical, Con-
cord, CA) and steamed for 20 min at 95 °C in a
vegetable steamer. After heating, the slides were allowed
to cool and then rinsed with PBS for three times. After
washing, the slides were incubated with 0.1% Triton in
PBS for another 10 min. The slides were then washed
with PBS for three times for 5 min each. Endogenous
peroxidase activity was quenched with 3% hydrogen per-
oxide in methanol for 15 min. After being washed three
times in PBS, slides were blocked with non-fat milk (5%)
in PBS-tween (0.1%) for another 2 h in a humidity
chamber at RT. Slides were incubated overnight with
primary antibody and respective isotype control in a hu-
midity chamber: rabbit anti-MAA and rabbit-IgG (dilu-
tion 1:1000; Abcam, Inc., Cambridge, MA). After being
washed, slides were incubated with the appropriate HRP
conjugated goat-anti-rabbit IgG (dilution 1:1000; Jackson
ImmunoResearch Laboratories, Inc., Grand Island, NY)
secondary antibody in a humidity chamber. After 1 h,
slides were rinsed and developed with Chromogen sub-
strate (IMMPACT DAB, Vector, Burlingame, CA)
followed by counter staining with 1% Meyer’s
hematoxylin. Finally the slides were dehydrated through a
series of ethanols and fixed with Safeclear II™ tissue clear-
ing agent.
Chemokine Assay
Murine, keratinocyte chemoattractant (KC; CXCL1) level
was determined in BAL fluid according to the manufac-
turer's instructions using a commercially available ELISA
kit (R&D Systems, Minneapolis, MN).
Lung slice protocol
Lung slices were prepared as previously described [20].
Briefly, C57BL/6 mice, between 7 and 9 weeks old, were
sacrificed by isoflurane overdose. Lungs were allowed to
deflate after which a syringe filled with a warm (37 °C)
solution of 2% agarose (type VII or VII-A: low gelling
temperature; Invitrogen, Carlsbad, CA, USA) in Hanks
Balanced Salt Solution (HBSS; pH 7.4) was slowly in-
stilled into the lung until fully inflated. Immediately after
agarose inflation, the lungs were washed with ice-cold
HBSS, packed with ice and allowed to cool at 4 °C for
30–45 min. The lung lobe was sectioned into slices
150 μm thick using Electron Microscopy Sciences Tissue
slicer (OTS 4500).
Sapkota et al. Respiratory Research  (2017) 18:36 Page 3 of 10
Sections of the lung were then transferred to wells of a
24-well plate and maintained with DMEM supplemented
with 10% FBS, antibiotics, and antimycotics at 37 °C and
10% CO2 for at least 5 days prior to treatment. Twenty-
four hours prior to treatment, media was changed to
serum free media. Lung slices were then treated with
SPD-MAA for 24 h. After 24 h the supernatant was col-
lected and stored at −80 °C for further chemokine ana-
lysis. Lung slices from each treatment were collected
and homogenized in cell lysis buffer and the protein
concentration (mg/mL) was measured using the Brad-
ford assay [32]. The chemokine level was normalized to
the concentration of protein.
Real-time Quantitative RT-PCR (qRT-PCR)
RNA was isolated from the lung tissue using RNeasy mini
kit (Qiagen, Valencia, CA) following manufacturer instruc-
tions as previously described [33, 34]. After RNA isolation,
the concentration and purity of RNA was determined by
NanoDrop spectrophotometer. TaqMan reverse transcrip-
tion kit (Applied Biosystems, Branchburg, NJ) was used to
synthesize DNA from 100 ng of template RNA purified
from lung tissue. Real-time quantitative PCR was per-
formed on the cDNA using the following reaction: 1×
TaqMan master mix and mouse CD204 primer (Applied
Biosystems, Branchburg, NJ; Mm00446214_m1) and
probe mix in 25-μl reactions in a 96-well plate in dupli-
cate. The plate was placed in an ABI Prism 7500 Sequence
detection system (Applied Biosystems). Reactions were
carried out for 2 min at 50 °C, 10 min at 95 °C, then 40 cy-
cles of 15 s at 95 °C and 1 min at 60 °C. Data are reported
as fold-change from control.
SR-A1 ELISA
For measurement of SR-A1 expression on whole lung
tissue, the protein was isolated from the lung tissue. The
lung tissue was rinsed in PBS to remove excess blood.
The tissue was then homogenized in 500 μl of PBS at 4 °
C. The homogenate was then centrifuged at 15,000 g for
10 mins. After centrifugation, the supernatant was col-
lected and protein was measured using the Bradford
assay. The supernatant was used to perform the sand-
wich ELISA according to manufacturer’s instructions
(LifeSpan Bioscience Inc, Seattle, WA).
Statistical analyses
All data were analyzed using Graphpad Prism 5 (San
Diego, CA, USA). Results represent mean ± standard
error. One- and two-way ANOVA with Tukey post-hoc
test and one-sample t-test were used to analyze data for
statistical significance. P < 0.05 was accepted as statisti-
cally significant.
Results
SR-A1 KO mice showed decreased lung cellularity
following repetitive MAA instillation
Repetitive instillation of SPD-MAA has been previously
reported to increase cellular influx in lavage fluid in WT
mice. When SR-A1 KO mice were repeatedly instilled
with SPD-MAA (50 μg/mL) for 3 weeks, however, a sig-
nificant decrease (p < 0.01) in total lung lavage cells was
observed when compared to WT mice (Fig. 1). No dif-
ference was observed in both WT and SR-A1 KO mice
instilled with saline or non-adducted SPD. These data
suggest that SR-A1 could be important in SPD-MAA
mediated effects on lung cellularity. This result also sug-
gests that SPD-MAA mediated increases in total BAL
cellularity is SR-A1 dependent.
SR-A1 KO mice showed decreased neutrophil influx
following repetitive MAA instillation
Repeated instillation for 3 weeks of 50 μg/mL SPD-MAA
resulted in an increased influx of neutrophils in lung when
compared to the saline-instilled group (Fig. 2d). There
were no changes in eosinophils (Fig. 2a) or lymphocytes
(Fig. 2b). When SR-A1 KO mice were repeatedly instilled
with SPD-MAA, significantly (p < 0.01) fewer neutrophils
were observed when compared to SPD-MAA instilled
WT mice (Fig. 2d). Likewise, the seemingly decrease in
macrophages seen in WT mice after MAA instillation
compared to WT saline (Fig. 2c) is a result of the in-
creased neutrophils represented in the total 200 cells
counted for each treatment group. Saline and non–
adducted SPD instillation have no effect on the neutrophil
or macrophage count in the BAL fluid. These results sug-
gest that the decrease in total lung cellularity observed
after SPD-MAA instillation in SR-A1 KO mice was due to























Fig. 1 Total cell count in BALF after 3 weeks of intranasal instillation of
SPD-MAA. Total cell count in BALF from WT and SR-A1 KO mice after
intranasal instillation of saline, SPD-MAA (50 μg/mL) and SPD (50 μg/mL)
for 3 weeks. Values are presented as the mean ± SEM, n = 6-10 mice/
group. **P< .01 for saline vs SPD-MAA. ## P< .01 for WT vs SR-A1 KO
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These results also suggest that SR-A1 is important for
MAA-mediated neutrophil recruitment.
MAA adduct-stimulated chemokine release is SR-A1-
dependent in vitro
To determine the role of SR-A1 in MAA adduct-
stimulated KC levels in BAL samples from mice instilled
for 1 day, 1 week, 2 weeks or 3 weeks was also mea-
sured. No increase in KC release was observed over any
of the time periods in saline-instilled WT mice (Fig. 3a).
In WT SPD-MAA instillation group, there was a 3.5
fold (215.9 ± 65 pg) increase in KC release in the 1-
week (p < 0.001) and 2.7 fold (167.2 ± 8.944 pg) in-
crease in 2-week (p < 0.05) mice when compared to
the 1-day animals (61 ± 16.98 pg) (Fig. 3b). At 3 weeks,
KC release returned to baseline (Fig. 3b). In SR-A1
KO mice there was no significant increase in KC re-
lease over time in both saline-instilled (Fig. 3a) and
SPD-MAA instilled mice (Fig. 3b). In support of these
observations, ex vivo treatment with SPD-MAA re-
sulted in a significant increase (p < 0.001) in KC re-
lease from lung slices made from WT mice when
compared to media control treatment (Fig. 3c). In
contrast, a significant reduction (p < 0.0001) in KC re-
lease was observed from lung slices of SR-A1 KO
mice when compared with WT lung slices treated
with MAA (Fig. 3c). No increase in KC release was
observed over the time period of SPD instillation in
WT mice (data not shown). These data show that
SR-A1 is required for MAA-stimulated chemokine re-
lease in an in vitro lung slice model.
Repeated exposures to MAA adduct increased whole lung
SR-A1 expression
To determine the role of MAA adduct on lung SR-A1
(CD204) expression, lung tissue from WT mice instilled
with 50 μg/mL SPD-MAA for 3 weeks was used to meas-
ure SR-A1 message and protein expression. Repeated
MAA exposure resulted in significant increase (p < 0.05)
in SR-A1 message expression (almost twofold; Fig. 4a).
Consistent with the message expression, a significant in-
crease (p < 0.05) in SR-A1 protein expression was also ob-
served (Fig. 4b). No such increase in both SR-A1 message
and protein was seen in WT mice instilled with non-
adducted SPD (Fig. 4a, b). These data may be important
in explaining the increased inflammation in WT mice due
to repeated exposure to MAA adduct.
SR-A1 KO mice display reduced lung inflammation
following repeated MAA adduct instillation
Our previous study shows that repetitive exposures to
MAA adduct results in lung inflammation due to the
influx of inflammatory cells within the peri-bronchiolar
region of small airways [20]. To determine the role of
SR-A1 on such inflammation, SR-A1 KO mice were in-





























































Fig. 2 Differential white blood cell counts in BALF collected after intranasal administration of SPD-MAA, SPD or saline. Differential cell eosinophils
a lymphocytes b macrophages c and neutrophils d count in BALF from WT and SR-A1 KO mice after intranasal instillation of saline, SPD-MAA
(50 μg/mL) and SPD (50 μg/mL) for 3 weeks. Values are presented as the mean ± SEM, n = 6–10 mice/group. **P < .01 for saline vs SPD-MAA. ## P
< .01 for WT vs SR-A1 KO
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and later paraffin-embedded whole lungs were sectioned
and stained for hematoxylin and eosin. In comparison to
WT mice (Fig. 5b), microscopic examination revealed
significantly fewer inflammatory cells within the peri-
bronchiolar region of the small airways of SR-A1 KO
mice exposed to MAA adduct (Fig. 5e). No such change
(influx of neutrophils) was observed in the lungs of mice
instilled with either saline (Fig. 5a, d) or non-adducted
SPD (Fig. 5c, f ) for both strains of mice.
SR-A1 KO mice display reduced immunoreactivity for
MAA adduct after repeated exposure
Previous studies show that SR-A1 is important for MAA












































Fig. 4 mRNA and protein levels of SR-A1 (CD204) in total lung tissue from WT mice. mRNA a and protein b levels of SR-A1 on whole lung tissue








































































Fig. 3 Neutrophil chemokine KC (CXCL1) in BAL and from lung slices. KC levels in BAL samples of mice instilled with saline a or SPD-MAA: 50 μg/
mL b were measured over 1d, 1–3 weeks time. Lung slices from both WT and SR-A1 KO mice were treated with media, SPD-MAA (100 μg/mL)
and non-adducted SPD (100 μg/mL) for 24 h c. After 24 h supernatant was collected and neutrophil chemokine KC release was measured. Values
are presented as the mean ± SEM of n = 3 independent experiments for lung slice and n = 5–16 mice per group for BAL KC release. ***P < .001
and *P < .05 for 1 and 2 weeks vs 1d instillation. *** P < .001 for media vs SPD-MAA. #### P < .0001 for WT vs SR-A1 KO
Sapkota et al. Respiratory Research  (2017) 18:36 Page 6 of 10
investigate that the decreased MAA-mediated effect in
SR-A1 KO mice could be due to decreased binding of
MAA adduct in lung tissue after 3-week instillation,
whole lung sections from both WT and SR-A1 KO mice
were stained for MAA adduct. Immunohistochemical
staining for MAA adduct demonstrated increased im-
munoreactivity along the bronchial epithelial and colum-
nar epithelial cells around the airways in WT mice
(Fig. 6b). No staining was observed in WT and SR-A1
KO mice instilled with saline (Fig. 6a, d) or non-
adducted SPD (Fig. 6c, f ). No staining was observed with
isotype control antibody (data not shown). These results
suggest that SR-A1 is important for MAA binding in air-
way as no such staining was detected in KO mice. This
could further explain the decreased response to MAA
adduct in SR-A1 KO mice.
Discussion
In this study, we demonstrated for the first time the
mechanistic role SR-A1 plays in regulating previously
a b c
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Fig. 5 Lung inflammation in lung after 3 weeks intranasal instillation of SPD-MAA. Both WT and SR-A1 KO mice were treated intranasally with
saline, SPD-MAA (50 μg/mL) and SPD (50 μg/mL) for 3 weeks. A representative 4–5 μm thick section of H and E stained of one mouse per
treatment group is shown (10 × magnification). WT Saline a, SPD-MAA b, SPD c and SR-A1 KO Saline d, SPD-MAA (E), SPD f. Line scale represents
approx. 100 μm. Arrow denotes the localization of inflammatory cells
d e f
a b c
Fig. 6 Representative lung tissue sections immunohistochemically stained for SPD-MAA. Immunohistochemical staining of SPD-MAA in lung
airways of both WT and SR-A1 KO mice treated intranasally with saline, SPD-MAA (50 μg/mL) and SPD (50 μg/mL) for 3 weeks. A representative
4–5 μm-thick section of one mouse per treatment group is shown (20 × magnification). WT Saline a WT SPD-MAA b WT SPD c and SR-A1 KO
Saline d, SR-A1 KO SPD-MAA e, SR-A1 KO SPD f. Line scale represents approx. 100 μm. Arrow denotes the staining and binding of MAA adduct
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reported MAA adduct-induced lung inflammation and
lung injury. Repetitive instillation of MAA adduct in
mouse lung resulted in inflammation as a result of neu-
trophil influx in the peri-bronchial region. Increased
lung cellularity and increased influx of neutrophils were
observed in the lungs of WT mice, but in SR-A1 KO
mice all of these effects caused by MAA adduct after re-
petitive instillation were significantly diminished. This
diminished inflammation in SR-A1 KO mice could be
further explained by a decrease in MAA adduct binding
to the airway cells. As a result, a decrease in KC release
from lung slices was observed. Similarly, no significant
increase in KC release in BAL from SR-A1 KO mice in-
stilled with SPD-MAA at 1 and 2 weeks was observed.
This could explain the decreased neutrophil influx in the
lung of the SR-A1 KO mice after MAA adduct instilla-
tion. An increase in KC release in BAL from WT mice
instilled for 1 and 2 weeks suggests earlier KC release,
leading to the recruitment of neutrophils in the airways
at 3 weeks. Our study is the first one to show the im-
portance of SR-A1 in MAA-induced lung inflammation
in mouse lung.
Previous studies show that macrophages scavenge
chemically modified proteins such as formaldehyde-
treated bovine serum albumin, maleylated albumin and
malondialdehyde-modified and acetylated low-density
lipoprotein by endocyting via a receptor mediated mech-
anism [35]. Highly reactive aldehydes formed as a result
of smoking and drinking have the ability to modify lung
proteins to produce a highly stable and immunogenic
product, malondialdehyde-acetaldehyde (MAA) adduct
[36, 37]. In contrast to individual protein adducts formed
by AA and MDA, which are unstable and dissociate rap-
idly, this MAA adduct is stable [38, 39] and can remain in
the lung for a long time. In mouse lung, surfactant pro-
teins A (SPA) and D (SPD) are equally MAA-adducted
when exposed to both ethanol and cigarette smoke [20].
This suggests that surfactant proteins are ideal targets for
MAA adduction in lung and therefore SPD-MAA used in
the study would be relevant to human subjects who abuse
alcohol and smoke cigarettes.
The presence of MAA adduct in liver, lung and re-
cently in the rheumatoid arthritis synovial tissue sug-
gests its importance as a marker of inflammation [40].
In lung, SR-A1 expressed on bronchial epithelial cells is
reported to bind MAA adduct and internalize them [29].
In support of this result, we earlier reported that SR-A1
was involved in MAA-adducted protein-stimulated,
PKC/ε-mediated KC production in mouse airway epithe-
lial cells [29]. We showed that MAA adduct binding to
bronchial epithelial cells is blocked when pretreated with
fucoidan, a ligand for scavenger receptor A [19]. Add-
itionally, a decreased antibody response to MAA-Alb in
SR-A1 KO mice is also reported [30]. Because SR-A1 is
extensively expressed in macrophages, a similar result was
also reported when macrophages from SR-A1 KO mice
were treated with MAA adduct. A decrease in the pro-
inflammatory cytokines, TNF alpha and IL-6, was ob-
served when compared to macrophages from WT mice
[18]. Willis et al. also reports that MAA-haptenated pro-
teins are preferentially bound by scavenger receptors on
macrophages, which internalize the ligands and shuttle
them to lysosomes [41]. Our result further supports these
published results that SR-A1 is one of major receptors in-
volved in the effects mediated by MAA-modified proteins
in mouse lung.
In the absence of SR-A1, we observed no accumula-
tion of MAA adducted protein in the lungs of the KO
mice, unlike the binding of SPD-MAA to epithelial cells
and macrophages of the lung in wild type mice. Secreted
surfactant has three different fates: (a) recycling, gov-
erned by the alveolar type II cell, followed by re-
secretion; (b) degradation followed by the synthesis of
new surfactant protein; and/or (c) removal from the sur-
factant system [42]. Constitutive mucociliary clearance
serves as the major whole lung removal mechanism for
surfactant. Cleared surfactant is swallowed into the
gastrointestinal tract and eventually excreted. Thus, the
likely outcome for unbound MAA-SPD in KO mice (and
to some extent in wild type mice as well) would be the
normative process of lung clearance.
There is a similarity between the mechanism by which
both oxidized LDL (ox-LDL) and modified MAA protein
initiate toxicity [43]. Both are recognized by scavenger
receptors and Ox-LDL is associated with the pathogen-
esis of atherosclerosis [44]. There are also various theor-
ies suggesting the specific feature of the ligand that
make it suitable for the scavenger receptor. Reaction of
amino groups of protein with short-chain α-hydroxy al-
dehydes may yield a moiety that is important for recog-
nition by scavenger receptor A [45]. Negative charges in
the ligands could be another important feature for bond-
ing reaction [46]. Change in protein confirmation after
binding with aldehydes could be another determinant in
receptor binding [47]. MAA adduct formed as a result of
Schiff base reaction between 2 mol of malondialdehyde
and 1 mol of acetaldehyde with lung protein, such as
SPD, therefore, may fulfill the above-mentioned require-
ments, making it a ligand for SR-A1.
Our study also showed a difference in MAA staining
in the lung after repeated intranasal instillation for
3 weeks in WT and SR-A1 KO mice. Interestingly, most
of the positive staining for MAA was seen in airway epi-
thelial cells, the cells that first come into contact with
MAA after intranasal instillation. Airway epithelial cells
express SR-A1 and take up MAA as previously reported
[29]. The remarkable finding of our study was that in
SR-A1 KO mice, significantly less MAA staining was
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observed. This further supports the observation that the
diminished response to MAA in SR-A1 KO mice is due
to less uptake of MAA by airway epithelial cells. Our re-
sults also suggest that binding of MAA to airway epithe-
lial cells is important to initiate the inflammatory
responses to MAA.
Our study also demonstrated an increase in SR-A1 ex-
pression after repetitive instillation of MAA adduct for
3 weeks. The increased inflammation in the lung of WT
mice after MAA instillation could be due to increased
binding as a result of increased expression of the SR-A1
on the lung. This modulation of SR-A1 expression in
lung is important as it could modulate the inflammatory
responses to MAA adduct. Chronic lung inflammation is
one of the characteristic features of COPD, which is pre-
dicted to be the third leading cause of death worldwide
by 2020 [48]. Smoking is the primary risk factor for COPD
[49] and about one-third of smokers are drinkers. This is
why it is important to study the role of co-exposure of
cigarette smoke and alcohol on lung inflammation. One of
the pathways through which this co-exposure could induce
lung injury is the formation of MAA adduct from reactive
aldehydes. Our results suggest that SR-A1 is important to
initiate MAA-mediated inflammation in lung. Previous
studies have also reported that genetic polymorphisms in
macrophage scavenger receptor-1 gene (MSR1) could result
in increased macrophage adhesion, receptor expression,
and reduced apoptosis [50]. It has been also linked to
COPD susceptibility [51].
Conclusions
In summary, this study demonstrates the functional role
of SR-A1 in MAA adduct-induced inflammation in lung.
SR-A1 is important for initiation of inflammation after
instillation of MAA as absence of SR-A1 is protective
against MAA mediated lung inflammation and injury.
Future studies involving individuals with genetic poly-
morphisms in SR-A1 would be important to better
understand the role of SR-A1 on susceptibility to lung
inflammation in smokers and drinkers.
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